On June 11, 2015, 3SBio (01530.HK) was successfully listed on the Main Board of HKEX. The market is eager for the IPO of 3SBio, and shares available for public offering are over-subscribed by more than 200 times and proceeds raised are over US$ 700 million.

3SBio Inc. is a pioneer in the bio-pharmacy industry in China, and has rich experiences and sound brand recognition in the development, production, marketing and sale of bio-pharmaceutical products. The Company’s two main products, TPIAO and EPIAO are the only commercialized recombinant human thrombopoietin (rhTPO) products in the world, and EPIAO is the absolute leader on the recombinant human erythropoietin (rhEPO) market with over 40% market share.

3SBio was listed on NASDAQ in 2007 and privatized in 2013 and delisted from NASDAQ. In August 2014, 3SBio started its listing in Hong Kong and completed the process successfully in 10 months.

Jingtian & Gongcheng has been 3SBio’s partner since 2001, and has provided PRC legal services for 3SBio for its US listing, privatization and Hong Kong listing.